Melanocortin Activation + Desire Signaling
PT-141, also known as Bremelanotide, is a melanocortin receptor agonist that acts centrally within the nervous system. Rather than influencing vascular pathways, it engages neural receptors associated with desire and arousal signaling.
Its mechanism centers on activation of melanocortin receptors in the brain — influencing neuroendocrine pathways involved in motivation and sexual response.
Functional Focus
Central Desire Regulation
Activates melanocortin receptors linked to sexual motivation pathways.
Neuroendocrine Signaling
Influences upstream arousal circuitry rather than peripheral blood flow.
Libido Support
Studied in contexts involving diminished sexual desire in both men and women.
Non-Hormonal Mechanism
Operates independently of testosterone or estrogen replacement.
CNS-Driven Response
Acts within central nervous system pathways responsible for sexual signaling.
Research Notes
Bremelanotide is FDA-approved for a specific indication under prescription supervision. Broader uses and formulations remain investigational.
Use should occur only under qualified medical guidance or within approved research contexts.